Skip to search formSkip to main contentSkip to account menu

hexamethylene bisacetamide

Known as: N,N'-Hexamethylenebisacetamide, Acetamide, N,N'-hexamethylenebis-, HMBA 
A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

AcetamidesAntineoplastic AgentsHematinics
NCIt Antineoplastic Agent Terminology

Narrower (1)

NSC 95580

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Differentiation induction as a treatment for hematologic malignancies
In many acute leukemias and some lymphomas, aberrant di€erentiation is a major feature of the malignant phenotype that often… 
1995
1995
Antisense oligodeoxynucleotide inhibition of delta protein kinase C expression accelerates induced differentiation of murine erythroleukaemia cells.
The potential regulatory role of delta protein kinase C (delta PKC) in murine erythroleukaemia cell differentiation was studied… 
1995
1995
Down-regulation of the cyclin A promoter in differentiating human embryonal carcinoma cells is mediated by depletion of ATF-1 and ATF-2 in the complex at the ATF/CRE site.
The human embryonal carcinoma cell line NEC14 can be induced to differentiate by the addition of N,N'-hexamethylene-bis-acetamide… 
1990
1990
Inhibition of induced melanogenesis in Cloudman melanoma cells by four phenotypic modifiers.
1989
1989
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was administered to patients with refractory malignant tumors… 
1988
1988
Relationship between transient DNA hypomethylation and erythroid differentiation of murine erythroleukemia cells.
The state of DNA methylation in mouse erythroleukemia (MEL) cells has been analyzed in relation to commitment to differentiation… 
Highly Cited
1987
Highly Cited
1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was tested in patients with refractory, solid tumors. Twenty… 
1987
1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I… 
1983
1983
Differentiation-defective mutants of mouse embryonal carcinoma cells: response to hexamethylenebisacetamide and retinoic acid.
Highly Cited
1977
Highly Cited
1977
Hexamethylene bisacetamide induces morphologic changes and increased synthesis of procollagen in cell line from glioblastoma multiforme.
Addition to hexamethylene bisacetamide (diacetyldiaminohexane) to cultures of a malignant mesenchymal cell line derived from a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)